2019年

≪英文≫

 

TFE3 Xp11.2 translocation renal cell carcinoma mouse model reveals novel therapeutic targets and identifies GPNMB as a diagnostic marker for human disease.

Baba M, Furuya M, Motoshima T, Lang M, Funasaki S, Ma W, Sun HW, Hasumi H, Huang Y, Kato I, Kadomatsu T, Satou Y, Morris N, Karim BO, Ileva L, Kalen JD, Wilan Krisna LA, Hasumi Y, Sugiyama A, Kurahashi R, Nishimoto K, Oyama M, Nagashima Y, Kuroda N, Araki K, Eto M, Yao M, Kamba T, Suda T, Oike Y, Schmidt LS, Linehan WM.

Mol Cancer Res. 2019 Aug;17(8):1613-1626.

 

MiR-204-5p: a novel candidate urinary biomarker of Xp11.2 translocation renal cell carcinoma.

Kurahashi R, Kadomatsu T, Baba M, Hara C, Itoh H, Miyata K, Endo M, Morinaga J, Terada K, Araki K, Eto M, Schmidt LS, Kamba T, Linehan WM, Oike Y.

Cancer Sci. 2019 Jun;110(6):1897-1908.

 

Impact of tumor size on patient survival after radical nephrectomy for pathological T3a renal cell carcinoma.

Sugiyama Y, Yatsuda J, Murakami Y, Ito N, Yamasaki T, Mikami Y, Ogawa O, Kamba T.

Jpn J Clin Oncol. 2019 May;49(5):465-472.

 

Clinical utility of androgen receptor gene aberrations in circulating cell-free DNA as a biomarker for treatment of castration-resistant prostate cancer.

Sumiyoshi T, Mizuno K, Yamasaki T, Miyazaki Y, Makino Y, Okasho K, Li X, Utsunomiya N, Goto T, Kobayashi T, Terada N, Inoue T, Kamba T, Fujimoto A, Ogawa O, Akamatsu S.

Sci Rep. 2019 Mar 11;9(1):4030. doi: 10.1038/s41598-019-40719-y.

 

Manipulation of Nephron-Patterning Signals Enables Selective Induction of Podocytes from Human Pluripotent Stem Cells.

Yoshimura Y, Taguchi A, Tanigawa S, Yatsuda J, Kamba T, Takahashi S, Kurihara H, Mukoyama M, Nishinakamura R.

J Am Soc Nephrol. 2019 Feb;30(2):304-321.